Every DEF 14A that Cross Country Healthcare Inc (CCRN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CCRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCRN filings page.
Cross Country Healthcare is asking stockholders to vote at its virtual 2026 Annual Meeting on May 11, 2026, including electing six directors, ratifying Deloitte & Touche as auditor, approving 2025 executive pay on an advisory basis, and amending the 2024 Omnibus Incentive Plan.
CEO Kevin Clark has returned with a mandate to restore growth after a terminated merger with Aya Healthcare that slowed 2025 momentum. The company highlights a debt‑free balance sheet and 2025 revenue of about $1.1 billion, Adjusted EBITDA of $26.8 million (2.5% margin), Adjusted EPS of $0.02, strong cash flow of $48.3 million, and repurchases of 0.8 million shares for $6.5 million.
The six‑member board is majority independent, with robust committee oversight of audit, compensation, governance, cybersecurity, environmental and climate risks, and artificial intelligence. Executive pay is heavily performance‑based; 2025 cash incentives paid out well below target and no performance shares were earned for the 2023–2025 cycle, while new 2025 equity awards were granted late in the year with multi‑year vesting and performance goals tied to cumulative Adjusted EBITDA and Adjusted EPS.
Cross Country Healthcare (CCRN) set its 2025 Annual Meeting for December 9, 2025 at 12:00 p.m. ET, to be held virtually at www.virtualshareholdermeeting.com/CCRN2025. Stockholders of record as of October 14, 2025 may vote.
The agenda includes three items: elect seven director nominees for one-year terms; ratify Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2025; and approve, on a non-binding advisory basis, 2024 executive compensation.
The company notes its proposed merger with Aya Healthcare, Inc. is expected to close in the fourth quarter of 2025; the Annual Meeting will not be held if the merger closes before December 9.
Governance highlights include a seven-member Board with a Lead Independent Director and fully independent Audit, Compensation, and Governance & Nominating Committees. 2024 results cited include revenue above $1.3 billion, Adjusted EBITDA of $49.1 million (3.7% margin), Adjusted EPS of $0.46, strong cash flow of $120.1 million, repurchases of 2.4 million shares for $36.8 million, and no outstanding long-term debt.